Assessing Amicus Therapeutics Valuation After a 48.3% One Month Share Price Surge [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Let's set the stage so you can judge whether this biotech fits your return and risk appetite. The stock has surged recently, climbing about 34.4% over the last week and 48.3% over the past month, bringing its year to date gain to 52.3% and 44.7% over the last year, despite still being down 41.5% over five years. That kind of rebound naturally raises questions about whether the market is finally catching up to the story or getting ahead of itself. Some of this momentum has been tied to growing optimism around Amicus Therapeutics' rare disease pipeline and the commercial progress of its flagship therapies. This has helped reset expectations for its long term revenue potential. At the same time, regulatory and competitive updates across the rare disease space have sharpened investors focus on which companies have truly durable advantages, putting Amicus more squarely under the microscope. Right now, our valuation framework gives Amicus Therapeutics a 5/6 value score , suggesting it
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating. They now have a $14.50 price target on the stock.MarketBeat
- Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Citigroup Inc.. They now have a $14.50 price target on the stock, down previously from $17.00.MarketBeat
- Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics (NASDAQ:FOLD) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public ShareholdersPR Newswire
FOLD
Earnings
- 11/4/25 - Beat
FOLD
Sec Filings
- 12/19/25 - Form 144
- 12/19/25 - Form DEFA14A
- 12/19/25 - Form 8-K
- FOLD's page on the SEC website